Eleveted, night view of Makati, the business district of Metro Manila.

In brief

The Philippine Competition Commission (PCC) has identified the health and pharmaceuticals industries as one of its priority sectors of enforcement for year 2020. Coupled with the increased demand for improved access to healthcare and affordable medicine resulting from the COVID-19 pandemic, we expect the PCC to intensify its monitoring of participants in the Philippine pharmaceutical markets.


Contents

The PCC had recently published an issues paper and a policy note identifying the key challenges and potential competition issues in the Philippine pharmaceutical industry.

To aid and assist you in navigating through these new developments, we have summarized the PCC’s policy note and issues paper, and have likewise included other resources which you may use as reference to ensure your company’s continued compliance with the Philippine Competition Act (“PCA“) and its implementing rules and regulations (“PCA-IRR“).

We hope you find this useful and we welcome any feedback. Moreover, if you would like to discuss relevant or similar issues with us, please let me know and we can arrange a more bespoke discussion at your convenience.

Kind Regards,

Maria Christina Macasaet-Acaban
Partner and Head
Competition Focus Group
Healthcare & Life Sciences Industry Group

Read full alert here

*Authored by Quisumbing Torres, a member firm of Baker & McKenzie International, a Swiss Verein. Please contact QTInfoDesk@quisumbingtorres.com for inquiries.

Previous articleEMEA: COVID-19 Life Sciences Survey (Updated)
Next articleNorth America: Beating the competition – North American Antitrust Group Podcast